NR4A1 and ductal breast carcinoma in situ: However, it is less reliable at differentiating invasive cancer from DCIS, may be limited in some cases in the assessment of tumour grade and prognostic/predictive markers such as hormone receptors and Her-2/neu, has a relatively high inadequate rate and is more time consuming for pathologists.